ClinicalTrials.gg
CompletedNCT01571583REPLACEUpdated Jun 30, 2016

An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation

A Phase 3 interventional study of Telaprevir and Pegylated interferon alfa-2a in Chronic Hepatitis C Virus (HCV) Infection, sponsored by Janssen-Cilag International NV. Completed at 21 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-06-30.

Sponsored by Janssen-Cilag International NV (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
74
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing telaprevir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. telaprevir · Hepatitis C, Chronic.

Enrollment
11th of 27
74 · median 54
Started
2012
with 8 others
Phase 3
12 of 27
none open now
Registered
15th of 27
by date
Lead sponsor
3 of 27
Janssen-Cilag International NV

Among the 27 studies testing telaprevir in Hepatitis C, Chronic, this one is the 11th largest by enrollment, is one of 9 that started in 2012, is one of 12 in phase 3, and was the 15th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 27 studies testing telaprevir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About telaprevir

telaprevir: first FDA approval 2011 (INCIVEK), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 27 studies testing telaprevir in Hepatitis C, Chronic as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness of telaprevir in combination with Peg-IFN-alfa-2a and ribavirin in stable liver transplant patients with chronic hepatitis C virus (HCV) genotype 1.

Read the detailed description

This is an open-label (all people know the identity of the intervention), multicenter study in genotype 1 chronic HCV infected liver transplant patients who will be treated for 12 weeks with telaprevir 750 mg every 8 hours given in combination with Peg-IFN-alfa-2a and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone. The total treatment duration will be 48 weeks. Safety will be evaluated throughout the study and will include evaluations of adverse events, clinical laboratory tests, electrocardiogram, vital signs, and physical examination.

03

Conditions studied

  • Chronic Hepatitis C Virus (HCV) Infection

Keywords

  • Chronic HCV infection
  • Genotype 1 chronic HCV
  • Liver transplantation
  • Hepatitis C
  • Hep C
  • HCV
  • Telaprevir
  • Pegylated-Interferon-alfa-2a
  • Ribavirin
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • First time liver transplant recipient whose primary pre-transplant diagnosis was chronic genotype 1
  • More than 6 months to 10 years post-liver transplant
  • Patient did or did not receive treatment for HCV prior to liver transplantation
  • Patient must agree to have a liver graft during the screening period unless they had a biopsy within three months of the screening period (for patients between 6 months and one year post transplant) or within six months of the screening period (for patients who are more than one year post transplant)
  • A female patient of and a nonvasectomized male patient who has a female partner of childbearing potential must agree to the use of 2 effective methods of from screening until 6 months (female patient) or 7 months (male patient) after the last dose of ribavirin

Exclusion criteria

Exclusion Criteria:

  • Patient is currently infected or co-infected with of another genotype than genotype 1
  • Patient received treatment for hepatitis C following liver transplantation
  • Patient has history of decompensated liver disease or shows evidence of significant liver disease in addition to hepatitis C
  • Patient with or virus co-infection
  • Patient with active malignant disease or history of malignant disease within the past 5 years (with the exception of treated basal cell carcinoma or hepatocellular carcinoma)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Telaprevir+Peg-IFN-alfa-2a+Ribavirin

    Patients will be treated for 12 weeks with telaprevir in combination with Pegylated interferon alfa-2a (Peg-IFN-alfa-2a) and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone.

    Drug: Telaprevir · Drug: Pegylated interferon alfa-2a · Drug: Ribavirin

Interventions

  • Type=exact number, unit=mg, number=375, form=tablet, route=oral. Patients will receive 2 oral tablets (750 mg) every 8 hours for 12 weeks.

  • Type=exact number, unit=µg, number=180, form=injection, route=subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 48 weeks.

  • Type=exact number, unit=mg, number=200, form=tablet, route=oral. Starting from 600 mg (3 tablets) per day on Day 1. This dose will become higher or lower based on blood results and the investigators opinion (to a goal of 1000 to 1200 mg/day \[5 to 6 tablets\] based on subject weight), twice daily regimen, for 48 weeks.

06

What researchers measure

Primary outcomes

  1. Number of patients achieving sustained virologic response (SVR) 12 planned

    SVR12 planned is defined as having plasma hepatitis C virus (HCV ) ribonucleic acid (RNA) level less than 25 IU/mL 12 weeks after the last planned dose of study medication.

    Time frame: Week 60

Secondary outcomes

  1. Number of patients achieving SVR12 planned(c)

    SVR12 planned(c) is defined as having undetectable plasma HCV RNA levels 12 weeks after the last planned dose of study drugs.

    Time frame: Week 60

  2. Number of patients achieving SVR24 planned

    SVR24 planned is defined as having plasma HCV RNA levels less than 25 IU/mL 24 weeks after the last planned dose of study medication.

    Time frame: Week 72

  3. Number of patients achieving SVR24 planned(c)

    SVR24 planned(c) is defined as having an undetectable plasma HCV RNA level 24 weeks after the last planned dose of study medication.

    Time frame: Week 72

  4. Number of patients having an undetectable HCV RNA level at Week 4 of treatment

    Time frame: Week 4

  5. Number of patients having an undetectable HCV RNA level at Week 12 of treatment

    Time frame: Week 12

  6. Number of patients having undetectable HCV RNA levels at Week 4 and Week 12 of treatment

    Time frame: Week 4 and Week 12

  7. Number of patients having an undetectable HCV RNA level at the actual end of treatment

    Time frame: Week 48

  8. Number of patients having an undetectable HCV RNA level at the planned end of treatment

    Time frame: Week 48

  9. Number of patients having less than 25 IU/mL at the planned end of treatment

    Time frame: Week 48

  10. Number of patients with on-treatment virologic failure

    Virologic failure is defined as patients who meet a virologic stopping rule and/or meet the definition of viral breakthrough.

    Time frame: Week 48

  11. Number of patients with relapse after undetectable HCV RNA at actual end of treatment

    Number of patients who relapse, defined as having confirmed detectable HCV RNA during the follow-up period after previous undetectable HCV RNA (less than 25 IU/mL, target not detected) at actual end of treatment.

    Time frame: Week 48

  12. Number of patients with relapse after undetectable HCV RNA at planned end of treatment

    Number of patients who relapse, defined as having confirmed detectable HCV RNA during the follow-up period after previous undetectable HCV RNA (less than 25 IU/mL, target not detected) at planned end of treatment.

    Time frame: Week 48

  13. Number of patients with relapse after previous HCV RNA less than 25 IU/mL at planned end of treatment

    Number of patients who relapse, defined as having confirmed detectable HCV RNA during the follow-up period after previous HCV RNA less than 25 IU/mL at planned end of treatment.

    Time frame: Week 48

  14. Number of patients with viral breakthrough

    Number of patients with viral breakthrough (defined as an increase more than 1 log in HCV RNA level from the lowest level reached, or a value of HCV RNA more than 100 IU/mL in patients whose HCV RNA has previously become less than 25 IU/mL during treatment).

    Time frame: Week 48

  15. Change from baseline in log HCV RNA values

    Change from baseline in log HCV RNA values at each time point during treatment.

    Time frame: Up to Week 52

  16. Number of patients who have changes in liver graft biopsy histology

    Time frame: Up to Week 72

  17. Number of patients with adverse events

    Time frame: Up to Week 72

07

Study locations

21 sites
  • Linz, Austria
  • Wien, Austria
  • Brussels, Belgium
  • Gent, Belgium
  • Leuven, Belgium
  • Liege, Belgium
  • Clichy, France
  • Marseille, France
  • Montpellier, France
  • Rennes Cedex N/A, France
  • Villejuif Cedex, France
  • Essen, Germany
  • Frankfurt A. M., Germany
  • Hannover, Germany
  • Leipzig, Germany
  • Münster, Germany
  • Barcelona, Spain
  • Madrid, Spain
  • Valencia, Spain
  • Birmingham, United Kingdom
  • London, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Apr 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2011
First posted
Apr 5, 2012
Start
Feb 2012
Primary completionActual
Apr 2014
CompletionActual
Jul 2014
Last update
Jun 30, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01571583
Responsible party
Sponsor
First posted
Apr 5, 2012
Start date
Feb 2012
Primary completion
Apr 2014
Completion
Jul 2014
Last update
Jun 30, 2016

Study contacts

Janssen-Cilag International NV, Belgium Clinical Trial
study director · Janssen-Cilag International NV

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telaprevir · Peginterferon alfa-2a · Ribavirin

Start the discussion